Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 501 to 550 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
501\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SPECTRIN SH3 DOMAIN BINDING PROTEIN 1; EPS8 BINDING PROTEIN; INTERACTOR PROTEIN ABLBP4; ABL-INTERACTOR PROTEIN 1 LONG; NAP1 BINDING PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.281309\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.0262\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.274126876\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ABI1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
502\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0401445\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.146476\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.274068789\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CDV3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
503\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT 7 (EIF-3 ZETA) (EIF3 P66) (EIF3D). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.367035\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.33921\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.274068294\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EIF3D\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
504\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ENIGMA PROTEIN; LIM DOMAIN PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0286746\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.104626\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.274067631\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
505\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE 1 (EC 1.1.1.205) (IMP DEHYDROGENASE 1) (IMPDH-I) (IMPD 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.183159\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.66836\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.274042432\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
IMPDH1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
506\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE 2 (EC 1.1.1.205) (IMP DEHYDROGENASE 2) (IMPDH-II) (IMPD 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.157432\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.574482\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.274041658\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
IMPDH2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
507\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GMP SYNTHASE [GLUTAMINE-HYDROLYZING] (EC 6.3.5.2) (GLUTAMINE AMIDOTRANSFERASE) (GMP SYNTHETASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.348668\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.27232\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.274041122\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GMPS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
508\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HEAT SHOCK FACTOR BINDING PROTEIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.135095\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.493083\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.273980243\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
509\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"RNA, U TRANSPORTER 1; SNURPORTIN-1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0968147\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.353554\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.273832852\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SNUPN\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
510\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.250323\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.914445\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.27374309\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KIAA1217\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
511\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEIN KINASE CLK2 (EC 2.7.1.-) (CDC-LIKE KINASE 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.131932\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.482648\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.273350351\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CLK2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
512\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEIN KINASE CLK3 (EC 2.7.1.-) (CDC-LIKE KINASE 3). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.1005\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.367745\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.273287196\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CLK3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
513\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUCLEAR PROTEIN SKIP (SKI-INTERACTING PROTEIN) (SNW1 PROTEIN) (NUCLEAR RECEPTOR COACTIVATOR NCOA-62). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.541777\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.98406\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.273064827\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SNW1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
514\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RNA-BINDING PROTEIN 9 (RNA BINDING MOTIF PROTEIN 9) (HEXARIBONUCLEOTIDE BINDING PROTEIN 2) (REPRESSOR OF TAMOXIFEN TRANSCRIPTIONAL ACTIVITY). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.424547\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.55794\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.27250536\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RBM9\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
515\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATAXIN 2-BINDING PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.534301\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.96129\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.272423252\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
516\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0480412\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.176368\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.272391817\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
METT10D\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
517\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.313715\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.15171\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.272390619\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UBAP2L\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
518\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
M-PHASE INDUCER PHOSPHATASE 2 (EC 3.1.3.48) (DUAL SPECIFICITY PHOSPHATASE CDC25B). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.510382\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.8743\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.272305394\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CDC25B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
519\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"BREAST CARCINOMA AMPLIFIED SEQUENCE 2; SPLICEOSOME ASSOCIATED PROTEIN, AMPLIFIED IN BREAST CANCER. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0379775\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.139495\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.272249901\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BCAS2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
520\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CDC5-LIKE; CDC5 (CELL DIVISION CYCLE 5, S. POMBE, HOMOLOG)-LIKE; CELL DIVISION CYCLE 5, S. POMBE, HOMOLOG-LIKE; CDC5-RELATED PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.333016\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.2232\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.272249836\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CDC5L\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
521\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RNA-BINDING PROTEIN WITH MULTIPLE SPLICING (RBP-MS). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.504359\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.85404\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.272032426\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RBPMS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
522\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"PRE-MRNA CLEAVAGE FACTOR I, 59 KDA SUBUNIT. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.694134\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.5522\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271974767\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
523\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"1,4-ALPHA-GLUCAN BRANCHING ENZYME (EC 2.4.1.18) (GLYCOGEN BRANCHING ENZYME) (BRANCHER ENZYME). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.142881\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.525483\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271904134\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GBE1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
524\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"GLYCOGEN PHOSPHORYLASE, MUSCLE FORM (EC 2.4.1.1) (MYOPHOSPHORYLASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0229997\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0845876\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.27190392\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PYGM\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
525\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"GLYCOGEN PHOSPHORYLASE, BRAIN FORM (EC 2.4.1.1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0231429\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0851144\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271903462\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PYGB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
526\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MYOSIN XV (UNCONVENTIONAL MYOSIN-15). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0249116\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.0916194\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.271903112\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
MYO15A\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
527\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"GLYCOGEN PHOSPHORYLASE, LIVER FORM (EC 2.4.1.1). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
PYGL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
528\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 12B ISOFORM A; MYOSIN PHOSPHATASE REGULATORY SUBUNIT; MYOSIN PHOSPHATASE, TARGET SUBUNIT 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.309836\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.13987\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271816962\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PPP1R12B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
529\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 12A; MYOSIN PHOSPHATASE, TARGET SUBUNIT 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.253813\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.933978\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271754795\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PPP1R12A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
530\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.260139\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.957852\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271585798\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RBM24\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
531\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RNA-BINDING REGION CONTAINING PROTEIN 1 (HSRNASEB) (SSDNA BINDING PROTEIN SEB4) (CLL-ASSOCIATED ANTIGEN KW-5). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.216511\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.797256\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271570236\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RBM38\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
532\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"KARYOPHERIN BETA 2B, TRANSPORTIN; IMPORTIN 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.404881\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.49189\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271387971\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TNPO2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
533\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SMALL NUCLEAR RIBONUCLEOPROTEIN F (SNRNP-F) (SM PROTEIN F) (SM-F) (SMF). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.232461\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.856628\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271367501\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SNRPF\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
534\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SMALL NUCLEAR RIBONUCLEOPROTEIN E (SNRNP-E) (SM PROTEIN E) (SM-E) (SME). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0399967\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.14739\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271366443\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
535\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
IMPORTIN BETA-2 SUBUNIT (KARYOPHERIN BETA-2 SUBUNIT) (TRANSPORTIN) (M9 REGION INTERACTION PROTEIN) (MIP). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.443276\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.63446\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271206392\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TNPO1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
536\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BROMODOMAIN-CONTAINING PROTEIN 3 (RING3-LIKE PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.122154\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.450566\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271112334\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BRD3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
537\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BROMODOMAIN-CONTAINING PROTEIN 2 (RING3 PROTEIN) (O27.1.1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.105783\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.390223\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271083457\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BRD2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
538\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BROMODOMAIN-CONTAINING PROTEIN 4 (HUNK1 PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.144761\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.534019\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.27107837\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BRD4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
539\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0778103\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.28704\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271078247\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SRBD1\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
540\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0358609\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.13229\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271077935\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LRRC4B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
541\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NAG14 PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0376313\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.138821\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271077863\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LRRC4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
542\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEIN REGULATOR OF CYTOKINESIS 1; PROTEIN REGULATING CYTOKINESIS 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.152328\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.561935\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271077616\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
543\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0431799\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.15929\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.27107728\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LRRC4C\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
544\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TESTIS-SPECIFIC BROMODOMAIN PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0996239\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.36752\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.27107069\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BRDT\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
545\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
QUAKING ISOFORM 6. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.59995\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.2133\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271065829\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
QKI\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
546\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ABHYDROLASE DOMAIN CONTAINING PROTEIN 2 (PROTEIN PHPS1-2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0497647\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.183589\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271065805\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ABHD2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
547\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CUG TRIPLET REPEAT, RNA BINDING PROTEIN 2; ELAV-TYPE RNA-BINDING PROTEIN; CUG TRIPLET REPEAT,RNA-BINDING PROTEIN 2; CUG TRIPLET REPEAT, RNA-BINDING PROTEIN 2; NEUROBLASTOMA APOPTOSIS-RELATED RNA-BINDING PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.24526\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.905006\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271003728\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CUGBP2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
548\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CUG TRIPLET REPEAT RNA-BINDING PROTEIN 1 (CUG-BP1) (RNA-BINDING PROTEIN BRUNOL-2) (DEADENYLATION FACTOR CUG-BP) (50 KDA NUCLEAR POLYADENYLATED RNA-BINDING PROTEIN) (EDEN-BP). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.267337\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.986471\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.271003405\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CUGBP1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
549\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SH3 DOMAIN-BINDING GLUTAMIC ACID-RICH PROTEIN (SH3BGR PROTEIN) (21- GLUTAMIC ACID-RICH PROTEIN) (21-GARP). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.046789\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.172653\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.271000214\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
SH3BGR\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
550\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LATS HOMOLOG 1. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
LATS1\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/